#transgene $TNG broke MA200#transgene $TNG broke MA200, closed on high volume. Could see a violent move into 1.75 and then above 2.00
−0.224EUR
−22.33 MEUR
1.18 MEUR
35.03 M
About TRANSGENE EUR0.50
Sector
Industry
CEO
Alessandro Riva
Website
Headquarters
Strasbourg
Employees (FY)
158
Founded
1979
ISIN
FR0005175080
FIGI
BBG00JHW1490
Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. Its products include TG4001, TG4050, TG6002, BT-001 & TG6050. The company was founded in December 1979 and is headquartered in Strasbourg, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0OCQ is 1.480 EUR — it has decreased by 0.54% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange TRANSGENE EUR0.50 stocks are traded under the ticker 0OCQ.
TRANSGENE EUR0.50 is going to release the next earnings report on Sep 24, 2024. Keep track of upcoming events with our Earnings Calendar.
0OCQ stock is 0.54% volatile and has beta coefficient of 0.19. Check out the list of the most volatile stocks — is TRANSGENE EUR0.50 there?
0OCQ earnings for the last quarter are −0.18 EUR per share, whereas the estimation was −0.24 EUR resulting in a 25.00% surprise. The estimated earnings for the next quarter are −0.21 EUR per share. See more details about TRANSGENE EUR0.50 earnings.
TRANSGENE EUR0.50 revenue for the last quarter amounts to 4.30 M EUR despite the estimated figure of 3.80 M EUR. In the next quarter revenue is expected to reach 6.70 M EUR.
Yes, you can track TRANSGENE EUR0.50 financials in yearly and quarterly reports right on TradingView.
0OCQ stock has risen by 34.30% compared to the previous week, the month change is a 41.63% rise, over the last year TRANSGENE EUR0.50 has showed a 27.09% decrease.
0OCQ net income for the last quarter is −6.43 M EUR, while the quarter before that showed −15.90 M EUR of net income which accounts for 59.59% change. Track more TRANSGENE EUR0.50 financial stats to get the full picture.
Today TRANSGENE EUR0.50 has the market capitalization of 133.73 M, it has increased by 17.70% over the last week.
No, 0OCQ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0OCQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TRANSGENE EUR0.50 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 158.00 employees. See our rating of the largest employees — is TRANSGENE EUR0.50 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TRANSGENE EUR0.50 technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TRANSGENE EUR0.50 stock shows the sell signal. See more of TRANSGENE EUR0.50 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on TRANSGENE EUR0.50 future price: according to them, 0OCQ price has a max estimate of 5.40 EUR and a min estimate of 3.50 EUR. Read a more detailed TRANSGENE EUR0.50 forecast: see what analysts think of TRANSGENE EUR0.50 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TRANSGENE EUR0.50 EBITDA is −33.81 M EUR, and current EBITDA margin is −2.86 K%. See more stats in TRANSGENE EUR0.50 financial statements.